Together is a new resource for anyone affected by pediatric cancer - patients and their parents, family members, and friends.Learn More
Anti-PD-1 Monoclonal Antibody MK-3475; Lambrolizumab; MK-3475
Pembrolizumab (Keytruda®) is a type of immunotherapy called a monoclonal antibody. This medicine works by targeting a protein called PD-L1. Pembrolizumab is considered a type of immunotherapy because it helps the patient’s immune system to attack cancer cells. It is also a targeted therapy because the medicine is specific to certain cell features and “targets” those cells.
Pembrolizumab is usually given as an IV infusion once every 3 weeks. Blood pressure, heart rate, breathing, and temperature will be checked regularly during and after the infusion to watch for infusion-related side effects.
Patients will have regular blood draws to check blood counts and glucose levels and to monitor kidney, liver, and thyroid function.
Given as a liquid into a vein by IV
Not all patients who take pembrolizumab will experience these side effects. Common side effects are in bold, but there may be others. Please report all suspected side effects to your doctor or pharmacist.
Be sure to discuss these and other recommendations with your doctor or pharmacist.